A high-level delegation from the Saudi Food and Drug Authority (SFDA), led by H.E. Dr. Hisham Aljadhey, CEO of SFDA, visited the global headquarters of BGI Group on November 4. The delegation was warmly received by Wang Jian, Co-Founder and Chairman of BGI Group, Yin Ye, CEO of BGI Group, Zhao Lijian, CEO of BGI Genomics, and other senior executives of BGI Group. The visit marked a pivotal step toward enhancing cooperation between the two organizations in the fields of genetic research and bioinformatics.

H.E.Dr. Aljadhey and his team engaged in in-depth discussions with BGI Group leadership on potential cooperation opportunities, particularly in the localization of cutting-edge technologies in the Kingdom of Saudi Arabia. The discussions explored avenues for joint research, investment, and technology transfer, with a focus on fostering local expertise and infrastructure in Saudi Arabia. Both parties expressed a shared commitment to advancing genetic research and enhancing the capabilities of bioinformatics in the region.

The Saudi delegation was warmly received by the BGI Group.

During the visit, the SFDA delegation gained valuable insights into BGI Group’s significant advances in genomics research, disease prevention and control, and smart laboratory technologies. The SFDA delegation highly recognized BGI Group’s innovative achievements and breakthrough technologies in genomics and life sciences, as well as their shared vision for advancing global health science and technology.

In July 2023, during the 10th Arab-China Business Conference in Riyadh, Dr. Yin Ye, CEO of BGI Group, highlighted the importance of making technological advancements accessible to all through scientific sharing for the benefit of humanity. At the conference, Dr. Aljadhey praised the collaboration with BGI Group and the high quality of their products. He stressed that the future lies in biotechnology, gene therapy, med-tech, and AI, noting that collaboration between China and Arab countries could lead to remarkable achievements.